Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Chemosensitization/Potentiation Therapy Clear all
Withdrawn Phase 2 Interventional

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00085345
View directory record Official record
Conditions
Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
Interventions
arsenic trioxide, ascorbic acid, melphalan, chemosensitization/potentiation, chemotherapy
Drug · Procedure
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Glendale, Arizona • Bakersfield, California • Campbell, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Sep 23, 2026, 8:06 PM EDT
Withdrawn Early Phase 1 Interventional

Long-term Potentiation Disruption Underlying Cognitive Impairment in ECT

NCT06733558
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder II
Interventions
Electroconvulsive Therapy
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 2 Interventional Results available

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

NCT01581970
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Cyclophosphamide, Cetuximab
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 1 Interventional

O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors

NCT00002604
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
O6-benzylguanine, carmustine, chemosensitization/potentiation therapy
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Spinal Manipulation on Central Nervous System Activity Measured by Reflexive Calf Muscle Recruitment

NCT02848456
View directory record Official record
Conditions
Subluxation of Joint of Lumbar Spine
Interventions
Spinal Manipulation, Max Voluntary Isometric Contraction, SM+MVIC
Procedure
Lead sponsor
Grant Sanders
Other
Eligibility
20 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 2 Interventional

The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

NCT00035893
View directory record Official record
Conditions
HIV Seropositivity, HIV Infection
Interventions
poly I-poly C12U
Drug
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
10
States / cities
Fountain Valley, California • Los Angeles, California • Norwalk, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Not applicable Interventional Results available

Transcranial Direct Stimulation (tDCS) and Behavioral Intervention in Aphasia

NCT02226796
View directory record Official record
Conditions
Aphasia
Interventions
Transcranial direct current stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
20 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment

NCT02966340
View directory record Official record
Conditions
Alcoholism
Interventions
Prazosin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 1 Interventional

Gene Therapy for the Treatment of Brain Tumors

NCT00001328
View directory record Official record
Conditions
Brain Neoplasm, Neoplasm Metastasis
Interventions
Cytovene (Ganciclovir Sodium), G1TKSVNa.53 Producer Cell Line
Drug · Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
19 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 1 Interventional Results available

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

NCT02723864
View directory record Official record
Conditions
Neoplasms
Interventions
Veliparib + VX-970 + Cisplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Bethesda, Maryland • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 1 Interventional

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT00313599
View directory record Official record
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
lapatinib, paclitaxel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 23, 2026, 8:06 PM EDT
Withdrawn No phase listed Observational

A Quality of Life Study Using Insulin Potentiation Targeted LowDose (IPTLD) Chemotherapy and Nutrition Therapy in the Treatment of Cancer

NCT02598479
View directory record Official record
Conditions
Cancer
Interventions
IPTLD and nutrition therapy
Other
Lead sponsor
Best Answer for Cancer Foundation
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 23, 2026, 8:06 PM EDT
Active, not recruiting Not applicable Interventional

Transcranial Direct Current Stimulation in Conjunction With Individualized Physical Therapy for Individuals With Chronic Knee Pain

NCT06132412
View directory record Official record
Conditions
Knee Pain Chronic
Interventions
transcranial direct current stimulation, physical therapy
Device · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 1 Interventional

Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00066456
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
3-Dimensional Conformal Radiation Therapy, Chemosensitization/Potentiation Therapy, Docetaxel
Radiation · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Flumazenil for the Treatment of Primary Hypersomnia

NCT01183312
View directory record Official record
Conditions
Hypersomnia, Primary Hypersomnia, Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
Interventions
Flumazenil
Drug
Lead sponsor
Lynn Marie Trotti
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 1 Interventional

Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma

NCT00822848
View directory record Official record
Conditions
Sarcoma
Interventions
epirubicin hydrochloride, ifosfamide, sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, hypofractionated radiation therapy
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
15 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 23, 2026, 8:06 PM EDT
Not yet recruiting Not applicable Interventional

Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD)

NCT05509842
View directory record Official record
Conditions
Parkinson Disease
Interventions
rTMS
Device
Lead sponsor
University of Michigan
Other
Eligibility
45 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 1Phase 2 Interventional

Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer

NCT00083109
View directory record Official record
Conditions
Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Fluorouracil, Pharmacological Study, Suramin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia

NCT00512252
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AMD3100, Mitoxantrone, Etoposide, Cytarabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 11, 2016 · Synced Sep 23, 2026, 8:06 PM EDT
Active, not recruiting Not applicable Interventional

Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome

NCT01494324
View directory record Official record
Conditions
Liver Cancer
Interventions
CT guided percutaneous ablation
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 23, 2026, 8:06 PM EDT
Not listed No phase listed Observational

A Five-Year Quality of Life Study for Cancer Patients

NCT01539148
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Constantine A. Kotsanis
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Grapevine, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Not applicable Interventional Results available

Transcranial Direct Current Stimulation Potentiation of Fear Extinction in OCD

NCT05521074
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 23, 2026, 8:06 PM EDT
Recruiting Early Phase 1 Interventional

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

NCT07560878
View directory record Official record
Conditions
Major Depression
Interventions
D-Cycloserine (DCS), Continuous theta-burst stimulation (cTBS), Transcranial Magnetic Stimulation Sham, Memantine, Lorazepam (drug), Baclofen, Placebo
Drug · Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 23, 2026, 8:06 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

TMS for Investigating Memory Facilitation

NCT05462782
View directory record Official record
Conditions
Age-associated Memory Impairment
Interventions
Transcranial Magnetic Stimulation (TMS) Cone Coil, Transcranial Magnetic Stimulation (TMS) Sham Coil
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
60 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 23, 2026, 8:06 PM EDT